Diabetes Self-Management Blog

The Type 2 diabetes drug rosiglitazone (brand names Avandia, Avandamet, and Avandaryl) has continued to make headlines over the last month as a new warning, new prescribing recommendations, and new findings about one of its side effects have been published. As you may recall, an analysis of multiple clinical trials published earlier this year in The New England Journal of Medicine linked rosiglitazone to an increased risk of heart attack and triggered a storm of controversy about the drug’s safety (read more at "Type 2 Drug Avandia Linked to Increased Risk of Heart Attacks").

Here are the most recent developments:

New black box warning. On November 14, the U.S. Food and Drug Administration (FDA) announced that rosiglitazone would have new information added to its existing “black box” warning. (A black box warning, which is found on a drug’s label, is the strongest form of warning about a drug that the FDA requires.) The new information states that the analysis published earlier this year showed rosiglitazone to be associated with an increased risk of “myocardial ischemic events,” such as chest pain and heart attack, but that three other large studies did not confirm or exclude this risk. “In their entirety,” the warning says, “the available data on the risk of myocardial ischemia are inconclusive.”

Rosiglitazone’s original black box warning (which is shared by pioglitazone [Actos, Actoplus met, and duetact], the other member of the thiazolidinedione class of Type 2 diabetes drugs) was added on August 14 of this year and states that these drugs may worsen congestive heart failure. For more information about this warning, check out “New Data on Avandia; New Warnings for TZD Drugs.”

Rosiglitazone’s manufacturer, GlaxoSmithKline, has agreed to add this new warning to the drug’s label. It has also agreed to begin a new, long-term clinical trial comparing rosiglitazone and pioglitazone “head to head” to compare their levels of risk or benefit to the heart. Full results from this trial, however, will probably not be available until 2014.

New consensus statement. On November 27, the American Diabetes Association and the European Association for the Study of Diabetes published an updated “consensus statement” about the use of oral diabetes drugs in people with Type 2 diabetes. The statement recognized “additional hazards associated with the use of either thiazolidinedione, and rosiglitazone in particular may result in increased frequency of myocardial infarctions.” It also urged special caution regarding the use of these drugs in people who have, or are at risk of developing, congestive heart failure. You can read the full consensus statement here (Adobe Reader required).

The FDA has also advised doctors whose patients take rosiglitazone and have heart disease or are at risk of a heart attack to monitor these patients closely, and advises the patients to discuss their use of this drug with their doctors.

New clue about fracture risk. Another finding about the thiazolidinedione drugs that came to light this year was that both were linked to an increased incidence of bone fractures (see “Diabetes Drug Linked to Fracture Risk” and “Second Diabetes Drug Linked to Increased Fractures”). Now, a new study of mice has suggested a possible mechanism behind this phenomenon. Published this week in the journal Nature Medicine, the study found that rosiglitazone increased the activity of cells that normally break down bones in mice. (Other cells are responsible for building bone back up.) This finding led researchers to conclude that long-term treatment with rosiglitazone in humans may lead to osteoporosis through increased bone removal.

While the side effects of the thiazolidinedione drugs have been receiving a lot of attention lately, it is important to keep in mind that all diabetes drugs have side effects. If you have concerns about any prescription drug you take, you should discuss them with your health-care provider and decide on any changes together, based on your individual needs and medical history.


  1. I take it but the warnings are of concern.

    Posted by David Dallas-Midgley |

Post a Comment

Note: All comments are moderated and there may be a delay in the publication of your comment. Please be on-topic and appropriate. Do not disclose personal information. Be respectful of other posters. Only post information that is correct and true to your knowledge. When referencing information that is not based on personal experience, please provide links to your sources. All commenters are considered to be nonmedical professionals unless explicitly stated otherwise. Promotion of your own or someone else's business or competing site is not allowed: Sharing links to sites that are relevant to the topic at hand is permitted, but advertising is not. Once submitted, comments cannot be modified or deleted by their authors. Comments that don't follow the guidelines above may be deleted without warning. Such actions are at the sole discretion of DiabetesSelfManagement.com. Comments are moderated Monday through Friday by the editors of DiabetesSelfManagement.com. The moderators are employees of Madavor Media, LLC., and do not report any conflicts of interest. A privacy policy setting forth our policies regarding the collection, use, and disclosure of certain information relating to you and your use of this Web site can be found here. For more information, please read our Terms and Conditions.

Type 2 Diabetes
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)
Long Hours at Low-Income Jobs Linked to Increased Diabetes Risk (10/02/14)
Metformin Study Currently Recruiting (08/19/14)
New Metformin Combo Drug Approved for Type 2 Diabetes (08/13/14)

Oral Medicines
Statins May Reduce Risk of Nerve Damage, Other Diabetes Complications (09/18/14)
New Metformin Combo Drug Approved for Type 2 Diabetes (08/13/14)
FDA Approves New Oral Drug for Type 2 Diabetes (08/07/14)
New SGLT Drugs Coming (07/23/14)

Diabetes Research
Can Grapefruit Juice Prevent Weight Gain, Increase Insulin Sensitivity? (10/16/14)
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)
Long Hours at Low-Income Jobs Linked to Increased Diabetes Risk (10/02/14)
Statins May Reduce Risk of Nerve Damage, Other Diabetes Complications (09/18/14)

Diabetes News
Can Grapefruit Juice Prevent Weight Gain, Increase Insulin Sensitivity? (10/16/14)
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)
Long Hours at Low-Income Jobs Linked to Increased Diabetes Risk (10/02/14)
New Weekly Type 2 Diabetes Drug Approved (09/26/14)



Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.

Blood Glucose Self-Monitoring — Part 3: Smart Monitoring

10 Keys to Long-Term Weight Loss

Take Your Best Shot: Stay Up to Date on Vaccines

Complete table of contents
Subscription questions